Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA) – a phase 2a randomized placebo-controlled trial

Maher et al.

www.thelancet.com/respiratory Published online May 20, 2018

Categorised in: / May 28, 2018 12:45 pm / Published by

Tags:
> >